Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Change in Cash (2023 - 2026)

ArriVent BioPharma has reported Change in Cash over the past 4 years, most recently at $16.6 million for Q1 2026.

  • Quarterly results put Change in Cash at $16.6 million for Q1 2026, up 167.8% from a year ago — trailing twelve months through Mar 2026 was $12.2 million (up 104.57% YoY), and the annual figure for FY2025 was -$28.8 million, up 62.21%.
  • Change in Cash reached $16.6 million in Q1 2026 per AVBP's latest filing, up from -$67.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $167.0 million in Q1 2024 and bottomed at -$208.6 million in Q4 2024.
  • Median Change in Cash over the past 4 years was -$15.8 million (2024), compared with a mean of -$7.8 million.
  • Peak annual rise in Change in Cash hit 494.57% in 2024, while the deepest fall reached 2409.66% in 2024.
  • Over 4 years, Change in Cash stood at $9.0 million in 2023, then tumbled by 2409.66% to -$208.6 million in 2024, then surged by 67.81% to -$67.1 million in 2025, then skyrocketed by 124.67% to $16.6 million in 2026.
  • Business Quant data shows Change in Cash for AVBP at $16.6 million in Q1 2026, -$67.1 million in Q4 2025, and -$93000.0 in Q3 2025.